1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Generic Drug Opportunity Assessment : Avanafil (Stendra)

Generic Drug Opportunity Assessment : Avanafil (Stendra)

  • January 2014
  • -
  • Greystone Research Associates

Summary

Table of Contents

Greystone Research has identified a branded drug that represents an attractive opportunity for generic drug companies. Details of our findings are contained in an insightful assessment.

Overview

Stendra is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED). Stendra received FDA NDA approval in April 2012. In June 2013, the drug, which will be marketed outside the U.S. under the brand name Spedra, received EC approval to market the drug in the EU.
The drug is formulated as an oral tablet and is supplied in three dosages: 50 mg, 100 mg and 200 mg. Stendra is intended to be taken no more than once per day and based in clinical trial data has an onset of action of as little as 30 minutes. The drug has the same contraindications as those of competing PDE-5 inhibitors approved fro treating ED.
Vivus intends to market Stendra via third parties. An agreement for marketing in the U.S. was recently concluded and the company now anticipates market entry by the end of 2013.

The Market

For the treatment of ED, Stendra will compete with currently approved and marketed PDE5 inhibitors in the form of oral medications including Viagra (sildenafil citrate), marketed by Pfizer, Inc.; Cialis (tadalafil), marketed by Eli Lilly and Company; Levitra (vardenafil), comarketed by GlaxoSmithKline plc and Schering-Plough Corporation in the U.S.; and STAXYN (vardenafil in an oral disintegrating tablet, or ODT), co-marketed by GlaxoSmithKline plc and Merck & Co., Inc.

Report Highlights

Stendra – The Brand
Avanafil – The Product
Avanafil – The Market
Avanafil – The Opportunity
Manufacturing and Sourcing
Stendra Patents and Exclusivity
Therapeutic Class P4 Certifications
Generic First-to-File Revenue Opportunity
Business Risk Assessment
First-to-File – Probabilistic Scenario

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series:  Erectile Dysfunction Forecast in 29 Major Markets 2017-2027

Epiomic Epidemiology Series: Erectile Dysfunction Forecast in 29 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • March 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Erectile Dysfunction in 29 Major Markets Erectile dysfunction, also known as ED and impotence, is defined as the frequent inability ...

Erectile Dysfunction  - Market Insights, Epidemiology and Market Forecast-2023

Erectile Dysfunction  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Erectile Dysfunction - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

Penile Implants or Penile Prosthesis Market - Global Industry Analysis, Size, Share, Trends and Forecast, 2015 – 2023

Penile Implants or Penile Prosthesis Market - Global Industry Analysis, Size, Share, Trends and Forecast, 2015 – 2023

  • $ 4795
  • Industry report
  • April 2017
  • by Infinium

The global market for penile implants was valued at around USD 232 million in 2016 and is expected to reach around USD 270 million by 2023, growing at a CAGR of around 2.1% during the forecast period of ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.